The present disclosure relates to RNAi agents,e.g., double stranded RNAi agents, able to inhibit 17β-hydroxysteroid dehydrogenase type 13 (HSD17B13 or 17β-HSD13) gene expression. Also disclosed are pharmaceutical compositions that include HSD17B13 RNAi agents and methods of use thereof. The HSD17B13 RNAi agents disclosed herein may be conjugated to targeting ligands to facilitate the delivery to cells, including to hepatocytes. Delivery of the HSD17B13 RNAi agentsin vivoprovides for inhibition of HSD17B13 gene expression. The RNAi agents can be used in methods of treatment of HSD17B13-related diseases and disorders, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hepatic fibrosis, and alcoholic or non-alcoholic liver diseases, including cirrhosis.本發明係關於能夠抑制17β-羥基類固醇去氫酶第13型(HSD17B13或17β-HSD13)基因表現之RNAi藥劑，例如雙鏈RNAi藥劑。亦揭示包含HSD17B13 RNAi藥劑之醫藥組合物及其使用方法。本文所揭示之該等HSD17B13 RNAi藥劑可偶聯至靶向配體以促進遞送至包含肝細胞在內之細胞。在活體內遞送該等HSD17B13 RNAi藥劑可抑制HSD17B13基因表現。該等RNAi藥劑可用於治療HSD17B13相關疾病及病症之方法中，該等疾病及病症包含非酒精性脂肪肝病(NAFLD)、非酒精性脂肪性肝炎(NASH)、肝纖維化及酒精性或非酒精性肝病(包含肝硬化)。
